Alendronate sodium hydrate (Synonyms: Adronat, Fosamax, G-704650, MK-217) |
| Catalog No.GC10348 |
L'alendronate (hydrate de sodium) est un inhibiteur de la farnésyl diphosphate synthase avec une IC50 de 460 nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 121268-17-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Alendronate is an inhibitor of bone resorption with IC50 value of 2nM [1].
Alendronate is a bisphosphonate. It is developed as a therapeutic agent in many bone disorders such as osteoporosis as well as Paget's disease and tumoral bone disease. Alendronate inhibits the bone resorption through binding to bone mineral and subsequently preventing the osteoclasts from ingesting them. It not only affects the function of osteoclasts but also alter the morphology of the cells. In the in vitro assay, alendronate shows effective antiresorbing potency with IC50 value of 2nM when treated with osteoclast suspension. In organ culture, alendronate inhibits resorption by embryonic long bones and cultured calvaria [1, 2].
References:
[1] Sahni M, Guenther H L, Fleisch H, et al. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. Journal of Clinical Investigation, 1993, 91(5): 2004.
[2] Bell N H, Johnson R H. Bisphosphonates in the treatment of osteoporosis. Endocrine, 1997, 6(2): 203-206.
Average Rating: 5 (Based on Reviews and 26 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *